IR vs KROS · P/E 49, rev $3.90B vs rev $32.0K
Ingersoll Rand Inc (IR) versus Keros Therapeutics Inc (KROS) — a side-by-side from cached financials, not a winner call.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
IR currently screens at market cap $28.27B and trailing P/E 48.8. KROS currently screens at market cap $208.8M.
Not investment advice. Open the IR and KROS stock pages for the full models.
Not investment advice.